Efficacy of a New Class III Drug Niferidil in Cardioversion of Persistent Atrial Fibrillation and Flutter

AIMS:To study the efficacy and safety of the new class III antiarrhythmic agent niferidil for pharmacological cardioversion in patients with persistent atrial fibrillation (AF) and atrial flutter (AFl). METHODS AND RESULTS:One hundred thirty-four adults (aged 57.8 ± 11 years, 90 males) were included...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cardiovascular pharmacology 2014-09, Vol.64 (3), p.247-255
Hauptverfasser:	Maykov, Evgeny B, Yuricheva, Yulia A, Mironov, Nikolay Yu, Sokolov, Sergey F, Golitsyn, Sergey P, Rosenshtraukh, Leonid V, Chazov, Evgeny I
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anti-Arrhythmia Agents - administration & dosage Anti-Arrhythmia Agents - adverse effects Anti-Arrhythmia Agents - therapeutic use Atrial Fibrillation - drug therapy Atrial Fibrillation - physiopathology Atrial Flutter - drug therapy Atrial Flutter - physiopathology Dose-Response Relationship, Drug Electrocardiography, Ambulatory Female Humans Male Middle Aged Piperidines - administration & dosage Piperidines - adverse effects Piperidines - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!